论文部分内容阅读
诺华公司有关血管紧张素受体Ⅱ抑制剂缬沙坦（Diovan,代文）用于未曾使用ACE抑制剂的心衰病人治疗的这一新适应证近日获得FDA的可批准信。
Novartis’ recent approval of the new indication for the treatment of patients with heart failure who have not used ACE inhibitors for the angiotensin II receptor antagonist valsartan (Diovan) is FDA approved.